Tango Therapeutics Appoints New CFO and Principal Accounting Officer to Drive Late-Stage Development

summarizeSummary

Tango Therapeutics announced a strategic overhaul of its financial leadership, appointing Matthew Gall as CFO and Jessica Newcomb as PAO, to support the company's transition into late-stage clinical development and potential commercialization.

check_boxKey Events

• CFO Transition

  Daniella Beckman departed as Chief Financial Officer, principal accounting officer, and principal financial officer, effective April 15, 2026.

• New CFO Appointed

  Matthew Gall, MBA, 49, was appointed Chief Financial Officer and principal financial officer, effective April 15, 2026. Mr. Gall previously served as CFO at Kalaris Therapeutics and iTeos Therapeutics.

• New CFO Compensation Package

  Mr. Gall will receive an annual base salary of $540,000, a target cash bonus opportunity of 40% of his base salary, and equity awards including an option to purchase 240,000 shares and 40,000 restricted stock units.

• New Principal Accounting Officer

  Jessica Newcomb, 40, currently Senior Vice President, Finance at the Company, was appointed Principal Accounting Officer, effective April 15, 2026.

auto_awesomeAnalysis

Tango Therapeutics has strategically revamped its financial leadership, appointing Matthew Gall as the new Chief Financial Officer and promoting Jessica Newcomb to Principal Accounting Officer. This move is explicitly aimed at accelerating the late-stage development of vopimetostat and preparing for potential commercialization, signaling a critical phase for the company. Gall brings extensive experience from other biopharmaceutical companies, and his substantial equity grant aligns his incentives with long-term shareholder value. While the departure of the previous CFO is noted, the company's narrative frames these changes as a proactive strengthening of leadership during a period of clinical progress and near 52-week highs.